Physician profile
John B Riley
NPI 1629573662
$2,928.85
in general payments reported to CMS, 2019-2025
11 companies · $1,468 in 2025
The $1,468 reported for 2025 was more than what 91% of Facial Plastic Surgery providers received nationally (typical 2025 total: $271).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $235 · 2022: $258 · 2023: $347 · 2024: $621 · 2025: $1,468.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,862 · Travel and Lodging: $573.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,862.19 |
| Travel and Lodging | $573.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stryker Corporation | $1,873.22 | 2023-2025 | Medline Industries, INC., Scopis Ent, Xpress Loprofile |
| Regeneron Healthcare Solutions, INC. | $317.86 | 2021-2025 | Dupixent |
| Medtronic, INC. | $281.80 | 2021-2023 | Propel, Stealthstation S8 Platform |
| Intersect Ent, INC. | $144.28 | 2022 | |
| Genzyme Corporation | $104.57 | 2024-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $61.03 | 2025 | Caplyta |
| Inspire Medical Systems, INC. | $53.11 | 2024 | Inspire |
| Integra Lifesciences Corporation | $28.69 | 2024 | Acclarent Aera |
| Neurent Medical Limited | $28.41 | 2025 | Neuromark System, Neuromark Radiofrequency Console |
| Ars Pharmaceuticals Operations, INC. | $18.65 | 2025 | Neffy |
| Glaxosmithkline, LLC. | $17.23 | 2025 | Nucala |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Riley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.